### The Swedish BioFINDER study

**Brief description**

Within the Swedish BioFINDER study, cognitively healthy elderly have been included to the prospective, longitudinal cohort study between 2008 and 2016. The participants were recruited from the Skåne University Hospital and the Malmö Diet and Cancer Study. Inclusion and exclusion criteria have been thoroughly validated and protocols have been published for all procedures. The cohort is prospective and longitudinal.

**Study design**

<table>
<thead>
<tr>
<th>Number of cases</th>
<th>Healthy elderly</th>
<th>Vascular cognition symptoms (GO &amp; MS)</th>
<th>Dementia cohort</th>
<th>Parkinsonian symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>100</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

**Inclusion criteria**

- **Neuropathology**
  - Alzheimer's disease
  - Lewy body disease
  - Amyotrophic lateral sclerosis

- **Epidemiology**
  - Age 60–80 years
  - No significant neurological or psychiatric disorder
  - Full understanding of German, English, or Swedish

- **Genetics**
  - Significant alcohol or substance misuse
  - Terminal cancer

- **PET**
  - Fulfilled criteria for early AD

- **MRI/CT**
  - Consecutive recruitment

- **CSF/blood $biomarkers**
  - CSF/blood $biomarkers

- **Other clinical measures**
  - Normal blood pressure
  - No significant cognitive symptoms

- **Time between follow-up visits (months)**
  - Every 12 months

**Registration of follow-up visits**

- **Parkinsonian symptoms**
  - Significant motor fluctuations
  - Significant levodopa tolerance
  - Significant dyskinesia

### Inclusion criteria

- **Healthy elderly**
  - Alzheimer's disease
  - Lewy body disease
  - Amyotrophic lateral sclerosis

- **Vascular cognition symptoms (GO & MS)**
  - Significant alcohol or substance misuse
  - Terminal cancer

- **Dementia cohort**
  - Fulfilled criteria for AD

- **Parkinsonian symptoms**
  - Significant motor fluctuations
  - Significant levodopa tolerance
  - Significant dyskinesia

### Registration of follow-up visits

- **Parkinsonian symptoms**
  - Significant motor fluctuations
  - Significant levodopa tolerance
  - Significant dyskinesia

### Inclusion criteria

- **Healthy elderly**
  - Alzheimer's disease
  - Lewy body disease
  - Amyotrophic lateral sclerosis

- **Vascular cognition symptoms (GO & MS)**
  - Significant alcohol or substance misuse

- **Dementia cohort**
  - Fulfilled criteria for AD

- **Parkinsonian symptoms**
  - Significant motor fluctuations

### Registration of follow-up visits

- **Parkinsonian symptoms**
  - Significant motor fluctuations
  - Significant levodopa tolerance
  - Significant dyskinesia